Diabetes

January 26, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pantoprazole  and Pyridoxamine (PAP) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 26/January/2017, 11.22 pm

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator […]
January 25, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Omeprazole and Pyridoxamine  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 25/January/2017, 11.08 am

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator […]
January 24, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Lansoprazole and Pyridoxamine  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 25/January/2017, 12.11 am

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator […]
January 23, 2018

Molecular therapy for Diabetic nephropathy (DN): Valsartan(Trade name: Diovan), an angiotensin converting enzyme inhibitor used in the treatment of hypertension, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 23/January/2018, 11.59 pm

Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the […]